|1.||Iams, Jay D: 11 articles (08/2015 - 09/2005)|
|2.||Caritis, Steve N: 11 articles (02/2014 - 09/2005)|
|3.||Rouse, Dwight J: 9 articles (02/2014 - 08/2007)|
|4.||Mercer, Brian M: 9 articles (02/2014 - 08/2007)|
|5.||Spong, Catherine Y: 9 articles (07/2013 - 09/2005)|
|6.||Varner, Michael W: 7 articles (04/2014 - 09/2005)|
|7.||Sorokin, Yoram: 7 articles (02/2014 - 08/2007)|
|8.||Thorp, John M: 7 articles (02/2014 - 09/2005)|
|9.||Peaceman, Alan M: 7 articles (07/2013 - 09/2005)|
|10.||Wapner, Ronald J: 6 articles (02/2014 - 09/2005)|
|1.||Premature Birth (Birth, Premature)
01/01/2007 - "Prophylactic administration of 17-alpha hydroxyprogesterone caproate (17OHPC) has proven to be effective in the prevention of preterm birth in women with singleton pregnancies with a previous preterm delivery. "
10/01/2011 - "Intramuscular 17 α-hydroxyprogesterone caproate (identical in formulation and manufacturing process to Makena™, thus hereafter referred to as Makena™) 250 mg once weekly, initiated at 16-20 weeks' gestation, was effective in reducing the risk of preterm birth in women with a singleton pregnancy at high risk of delivering preterm in a large, well designed, placebo-controlled trial (n = 463 randomized). "
01/01/2015 - "This study was aimed to investigate the association of treatment with 17-alpha hydroxyprogesterone caproate with GDM in pregnant women who are at risk for preterm birth (PTB). "
02/01/2014 - "This study evaluated the relationship between 17-alpha hydroxyprogesterone caproate plasma concentrations and the rate of spontaneous preterm birth in women with singleton gestation. "
06/01/2013 - "This was a secondary analysis of a randomized trial of 17-α hydroxyprogesterone caproate for prevention of preterm birth among nulliparous women with singleton gestations and cervices less than 30 mm by midtrimester ultrasonography. "
|2.||Endometrial Neoplasms (Endometrial Cancer)
02/01/1985 - "The data on 19 cases of primary endometrial carcinoma, stage I (mean age 28.0 years), cured by the administration of hydroxyprogesterone caproate without surgery and radiation therapy are presented. "
08/01/1995 - "Thirty-nine patients of endometrial cancer were treated with hydroxyprogesterone caproate, AG or combination of both, and their effects were compared. "
01/01/1985 - "Intramuscular administration of hydroxyprogesterone caproate in patients with endometrial carcinoma. "
12/01/1982 - "Adjuvant hydroxyprogesterone caproate in stage I endometrial carcinoma: changes in numbers and reactivities of some blood lymphocyte subpopulations."
01/01/1976 - "[Use of 19-nor-17 alpha-hydroxyprogesterone caproate in endometrial cancer]."
01/15/1980 - "A prospective trial was initiated in 1972 utilizing Depo-Provera in women with metastatic or recurrent endometrial adenocarcinoma to evaluate if the objective response and survival would be significantly improved in comparison to patients previously treated with Delalutin at a similar dose. "
05/01/1971 - "Postmenopausal women with recurrent or metastatic adenocarcinoma of the endometrium were treated with Delalutin (17-alpha-hydroxyprogesterone caproate), Depo-Provera (6-methyl-17-alpha-hydroxyprogesterone acetate), or Colprone (6,17-dimethyl-6-dehydroprogesterone). "
01/15/1980 - "Medroxyprogesterone acetate (Depo-Provera) vs. hydroxyprogesterone caproate (Delalutin) in women with metastatic endometrial adenocarcinoma."
08/01/1968 - "[Effect of hydroxyprogesterone caproate on carbohydrate tolerance in patients with endometrial hyperplasia and carcinoma]."
10/01/1961 - "Objective remission of metastatic breast carcinoma in a male who recieved 17-alpha hydroxy progesterone caproate (delalutin)."
04/01/1965 - "DELALUTIN AND ESTROGENS FOR THE TREATMENT OF ADVANCED MAMMARY CARCINOMA IN THE POSTMENOPAUSAL WOMAN."
|5.||Premature Obstetric Labor (Premature Labor)
03/01/2012 - "Single dose 17 alpha-hydroxyprogesterone caproate in preterm labor: a randomized trial."
08/01/2012 - "To evaluate the role of 17 α hydroxyprogesterone caproate (17OHPC) in the prevention of preterm labor in high risk asymptomatic patients with a history of preterm delivery. "
04/01/2010 - "We sought to identify maternal or clinical characteristics of women likely to develop preterm labor (PTL) at <34 weeks' gestation while receiving 17 alpha-hydroxyprogesterone caproate (17P) prophylaxis. "
08/01/2006 - "Further, a recent treatment option for preterm labor, 17 alpha-hydroxyprogesterone caproate, will also be discussed."
05/01/2006 - "Case report: hydroxyprogesterone caproate injection for prevention of preterm labor."
|2.||Medroxyprogesterone Acetate (Depo-Provera)
|4.||Suppositories (Vaginal Suppositories)
|8.||17-alpha-Hydroxyprogesterone (17 Hydroxyprogesterone)
|9.||Glucocorticoid Receptors (Glucocorticoid Receptor)
|5.||Neonatal Intensive Care